Highlights Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq Other stock markets 21:00:00 12/09/2024 BST			5-day change	1st Jan Change
20.24 ^USD	-3.37%		-12.97%	-33.87%

09-10	Arrowhead Pharmaceuticals' Plozasiran Receives FDA Breakthrough Therapy Designation	MT
09-10	Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	09-03	MT
Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran	09-03	DJ
Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint	09-03	MT
Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome	09-02	CI
Arrowhead Pharmaceuticals to Advance Two Drug Candidates in Clinical Trials on Obesity	08-14	MT
Arrowhead Pharmaceuticals to Advance Two Treatments for Obesity, Metabolic Diseases	08-14	DJ
Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies	08-14	CI
Arrowhead Pharmaceuticals Fiscal Q3 Loss Widens; Secures $500 Million Credit Facility From Sixth Street	08-08	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024	08-08	CI
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study	06-25	MT
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial	06-25	CI
Sector Update: Health Care Stocks Advance Monday Afternoon	06-24	MT
Arrowhead Says Potential Obesity Treatment Shows 'Promising' Preclinical Results -- Shares Rise	06-24	MT
Arrowhead Pharmaceuticals' Plozasiran Lowers Triglycerides in Phase 3 Trial; Shares Rise	06-03	MT
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome	06-03	CI
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia	05-28	CI
Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients	05-20	MT
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma	05-20	CI
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2	05-09	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Highlights

Filters